Compositions and methods for the treatment and prevention of Ebp pilus-related diseases

• US 9,839,682 B2
• Filed: 09/11/2015
• Issued: 12/12/2017
• Est. Priority Date: 09/12/2014
• Status: Active Grant

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Hultgren, Scott J., Caparon, Michael G., Pinkner, Jerome, Flores-Mireles, Ana L.
• Primary Examiner(s): NAVARRO, ALBERT MARK
• Application Number:
  US14/851,805
• Publication Number:
  US 20160074498A1
• Time in Patent Office: 823 Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 39/09 Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
• CPC Class Codes: C07K 16/1267 from Gram-positive bacteria

Abstract

The present invention relates to compositions comprising EbpA and methods of use thereof. Specifically, methods useful in the treatment and prevention of EbpA-associated infections.

Claims

1. A vaccine composition, the vaccine composition comprising:

SEQ ID NO;

3;

a pharmaceutically acceptable carrier; and

an immune effective amount of adjuvant.

2. The vaccine composition of claim 1, wherein SEQ ID NO:

3 comprises a fibrinogen-binding domain.

3. The vaccine composition of claim 1, wherein the vaccine composition comprises more than one SEQ ID NO:

3 linked together.

4. The vaccine composition of claim 1, wherein the vaccine composition comprises an immune effective amount of adjuvant selected from the group consisting of an aluminum salt, calcium salt, iron, zinc, acylated tyrosine, acylated sugars, saccharide, polyphosphazenes, biodegradable microspheres, monophosphoryl lipid A, lipid A derivatives quit A, Saponin, QS21, Freund'"'"'s Incomplete Adjuvant, Merck Adjuvant 65, AS-2, CpG oligonucleotides, bioadhesives and mucoadhesives, microparticles, liposomes, polyoxyethylene ether formulations, polyoxyethylene ester formulations, muramyl peptides or imidazoquinolone compounds.

5. The vaccine composition of claim 1, wherein the vaccine composition comprises a pharmaceutically acceptable carrier selected from the group consisting of a cream, ointment, suspension, lotion, powders, solutions, pastes, gels, aerosols, oil, liposome, nanoparticles, microemulsions, micelles, or dendrimers.